The intuitive software offers advantages over traditional predictive modeling platforms as it specifically helps users to identify chemistries with a high chance of success and focus expensive in-house resources. Used by pharmaceutical and biotech companies and research establishments globally, StarDrop 4.3 guides compound selection and design decisions in all stages of drug discovery.
StarDrop 4.3 is the first major update to StarDrop from Optibrium, helping scientists to select high quality drug candidates with confidence, improving efficiency and productivity.
StarDrop 4.3 is an interactive software platform that helps drug discovery scientists to guide their decisions while designing and prioritising molecules with the aim of achieving an optimal balance of properties. By combining predicted (in silico) properties for molecules with measured in vitro and in vivo data, this integrated desktop tool enables scientists to rapidly identify and design high quality molecules to meet their project's objectives.
The revolutionary software takes into account the potential errors to provide scientists with a rigorous analysis on which to make rational decisions. The data available in drug discovery typically have a high degree of uncertainty due to experimental variability or predictive error. StarDrop 4.3 is ground-breaking software that enables confident decisions to be made despite all of this uncertainty. Additional new enhancements to StarDrop 4.3 include the "Molecule View" feature which goes beyond traditional 'table' views of data sets and enables users to drag and drop properties to customize layout for viewing and printing and scroll through their compounds viewing all properties together. In the Molecule View, StarDrop's Glowing Molecule visualisation feature highlights regions of candidate molecules which may have the most influence on predicted properties, allowing users to test new ideas interactively with instant feedback. In addition, the toolbar allows users to easily switch between views facilitating quick access to key features.
New features unique to StarDrop 4.3 include more flexible data set views. Users can now freeze individual columns in the table view and organize the order and layout of properties across all views. Direct printing support enables users to print individual molecules with data from both table and molecule views. In addition, the range of powerful Gaussian Process methods in StarDrop's Auto-Modeller has been extended to provide new techniques for building classification models. Details of this approach and example applications can be read on Optibrium's Community site.
Dr. Matthew Segall, CEO of Optibrium, explains, "Optibrium is dedicated to providing software to guide decisions involving complex, uncertain data in an intuitive way. We work with project leaders and R&D directors to focus their resources, providing confident decision-making to improve efficiency.
StarDrop's intuitive, easy-to-use software also helps medicinal chemists to identify and design balanced compounds by combining all available data to make decisions. Furthermore, we offer powerful computational tools for computational chemists who can deploy their technology directly to project teams, efficiently integrating computational and experimental resources."
StarDrop 4.3 offers unique benefits across the spectrum of drug discovery, helping clients make business-critical choices. Benefits include better molecule design, faster selection and optimisation of molecules, reduced late-stage bottlenecks, strengthened pipelines and reductions in cost. The software provides a comprehensive range of features to support design and prioritization of high quality compounds including: probabilistic scoring; chemical space and glowing molecule visualisation; ADME QSAR models; P450 metabolism models and automatic model building.
About Optibrium Ltd
Optibrium (optibrium.com) is dedicated to providing software to guide decisions involving complex, uncertain data in an intuitive way. Optibrium's primary product, StarDrop, is focused on the drug discovery industry, helping scientists to guide decisions in the design and selection of high quality drug candidates. Optibrium was founded in 2009 as a spin-out of BioFocus DPI (formerly Inpharmatica). The founding group was responsible for the development of StarDrop from 2003 and, prior to this, research and development of related technologies since 1994. Based in Cambridge, UK, Optibrium has a global customer base ranging from top-ten pharmaceutical companies to small biotechs and academic groups.
For further press information please contact: Sarah Evans, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA, UK T: + 44 1477 539539 F: +44 1477 539 540 E: optibrium[.]scottpr.com.